Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan;52(1):25-35.
doi: 10.1016/j.pediatrneurol.2014.10.004. Epub 2014 Oct 16.

Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist

Petrus J de Vries  1 , Vicky H Whittemore  2 , Loren Leclezio  3 , Anna W Byars  4 , David Dunn  5 , Kevin C Ess  6 , Dena Hook  7 , Bryan H King  8 , Mustafa Sahin  9 , Anna Jansen  10
Affiliations

Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist

Petrus J de Vries et al. Pediatr Neurol. 2015 Jan.

Abstract

Background: Tuberous sclerosis complex is a multisystem genetic disorder with a range of physical manifestations that require evaluation, surveillance, and management. Individuals with tuberous sclerosis complex also have a range of behavioral, psychiatric, intellectual, academic, neuropsychologic, and psychosocial difficulties. These may represent the greatest burden of the disease. Around 90% of individuals with tuberous sclerosis complex will have some of these difficulties during their lifetime, yet only about 20% ever receive evaluation and treatment. The Neuropsychiatry Panel at the 2012 Tuberous Sclerosis Complex International Consensus Conference expressed concern about the significant "treatment gap" and about confusion regarding terminology relating to the biopsychosocial difficulties associated with tuberous sclerosis complex.

Methods: The Tuberous Sclerosis Complex Neuropsychiatry Panel coined the term TAND-tuberous sclerosis complex-associated neuropsychiatric disorders-to bring together these multidimensional manifestations of the disorder, and recommended annual screening for TAND. In addition, the Panel agreed to develop a TAND Checklist as a guide for screening.

Results: Here, we present an outline of the conceptualization of TAND, rationale for the structure of the TAND Checklist, and include the full US English version of the TAND Checklist.

Conclusion: We hope that the unified term TAND and the TAND Checklist will raise awareness of the importance of tuberous sclerosis complex-associated neuropsychiatric disorders and of the major burden of disease associated with it, provide a shared language and a simple tool to describe and evaluate the different levels of TAND, alert clinical teams and families or individuals of the importance of screening, assessment, and treatment of TAND, and provide a shared framework for future studies of tuberous sclerosis complex-associated neuropsychiatric disorders.

Keywords: autism; behavior; learning disorders; mental health; neurocognition; neuropsychological; psychiatric disorders; psycho-social.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement: None of the authors have any conflicts of interests related to the work in this article. V.H.W., L.L., A.W.B., K.C.E., and D.H. did not declare any potential conflicts of interest.

References

    1. Juelich K, Sahin M. Mechanism-based treatment in tuberous sclerosis complex. Pediatr Neurol. 2014;50:290–296. - PMC - PubMed
    1. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372:657–668. - PubMed
    1. O’Callaghan FJ, Shiell AW, Osborne JP, Martyn CN. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet. 1998;351:1490. - PubMed
    1. Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroad of multiple signaling pathways. Hum Mol Genet. 2005;14(S2):R251–R258. - PubMed
    1. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomized, placebo-controlled phase 3 trial. Lancet. 2013;381:125–132. - PubMed

Publication types

MeSH terms